Author Archives: Jimmy

Big Changes in Blood Pressure: A Simple Guide to the 2025 Hypertension Guidelines

The way doctors and pharmacists manage high blood pressure is about to change. The new 2025 AHA/ACC Hypertension Guidelines have been released, introducing significant, evidence-based updates designed to improve patient safety and provide more effective care.

Whether you are a patient or a healthcare provider, it’s important to understand these key shifts. Here’s a simple breakdown of what you need to know.

1. “Hypertensive Urgency” Gets a New Name and a Safer Approach

One of the biggest changes is the terminology. The term “hypertensive urgency” is now being replaced with

“severe hypertension”. This refers to a blood pressure reading higher than 180/120 mm Hg in a patient

without symptoms of acute target organ damage.

Why the change? The old term often led to unnecessary emergency department visits and the use of potent IV medications that could lower blood pressure too quickly, causing harm. The new approach for patients with asymptomatic severe hypertension is to:

  • Avoid IV medications in the hospital or ED.
  • Start well-tolerated oral medications.
  • Arrange for a follow-up appointment with a primary care provider or cardiologist within a few days.

2. A Smarter Way to Decide Who Needs Medication: The PREVENT Calculator

The new guidelines integrate the

PREVENT risk calculator, a more accurate and inclusive tool for predicting a person’s 10-year risk of heart attack or stroke. This calculator includes factors like kidney disease and social determinants of health to better guide treatment decisions.

The new rules are:

  • High-Risk Patients: If you have established cardiovascular disease, diabetes, chronic kidney disease, or a PREVENT risk score of 7.5% or higher, medication is now recommended if your blood pressure is 130/80 mm Hg or higher.
  • Lower-Risk Patients: If your blood pressure is between 130-139/80-89 mm Hg and your risk score is less than 7.5%, the first step is a 3-6 month trial of lifestyle changes. Medication is only recommended if blood pressure remains high after that period.

3. New Rules for Stroke and Brain Bleeds

The guidelines provide critical updates for managing blood pressure during neurological emergencies:

  • After an Ischemic Stroke (Post-Reperfusion): The guidelines now state that lowering systolic blood pressure below 140 mm Hg in the first 24-72 hours can be harmful and should be avoided. The goal is to maintain pressure between 140-180 mm Hg to ensure the brain gets enough blood flow to recover.
  • For a Brain Bleed (ICH): If the systolic pressure is between 150-220 mm Hg, the new target is to lower it to 130-140 mm Hg within the first 7 days. For extremely high pressures (>220 mm Hg), a continuous IV infusion is recommended over single “bolus” injections to prevent dangerous blood pressure swings.

4. Critical Updates for Managing Hypertension in Pregnancy

The 2025 guidelines emphasize safer and more proactive care for pregnant patients:

  • Treat Urgently: Severe hypertension (BP ≥160/110 mm Hg) during pregnancy is a medical emergency. Treatment must be started within 30-60 minutes to prevent a maternal stroke.
  • Treat Earlier: For chronic hypertension in pregnancy, treatment should now begin when blood pressure is 140-159/90-109 mm Hg to a target of <140/90 mm Hg.
  • Preeclampsia Prevention: Low-dose aspirin (81 mg daily) is strongly recommended for pregnant patients with chronic hypertension, starting at 12 weeks of gestation, to reduce the risk of preeclampsia.
  • Medication Safety: The list of contraindicated medications has been expanded. Common drugs like ACE inhibitors (e.g., lisinopril), ARBs (e.g., losartan), and the beta-blocker atenolol should be avoided during pregnancy due to risks to the fetus.

Guideline Resources

These updates represent a major step forward in hypertension management. For healthcare professionals seeking more information, the following resources are available:

 PubMed Search Guide for Pharmacists

PubMed Search Guide for Pharmacists

🔬 PubMed Search Guide for Pharmacists

Master evidence-based drug therapy research with advanced search strategies

🎯 Core Concepts You’ll Use Every Time

A. MeSH (Medical Subject Headings)

What: PubMed’s controlled vocabulary for indexing citations (e.g., Septic Shock[MeSH], Drug Interactions[MeSH]). Searching with MeSH enhances precision and recall by unifying synonyms under a single concept.

Pharmacy-Relevant MeSH Hierarchy Example:
Pharmaceutical Preparations [MeSH]
├── Dosage Forms [MeSH]
├── Drug Combinations [MeSH]
└── Pharmaceutical Solutions [MeSH]
💡 Pro Tip: Always check the MeSH Database first! Look up your concept, review the Scope Note and Entry Terms (synonyms), and consider using Major Topic or No Exp restrictions.

B. Essential Field Tags for Pharmacists

[ti]
Title only
High precision
[tiab]
Title OR Abstract
Balanced approach
[MeSH]
MeSH heading
Controlled vocabulary
[au]
Author
Find specific researchers

C. Boolean Logic & Critical Behavior

✅ Good Practice

vasopressin[tiab] OR argipressin[tiab]

Uses OR to combine synonyms within a concept

❌ Poor Practice

vasopressin argipressin

Missing Boolean operator – unpredictable results

⚠️ Important: Always capitalize AND/OR/NOT in PubMed. Quoting phrases disables Automatic Term Mapping – use quotes only when necessary for exact phrases.

💊 Essential Pharmacy MeSH Terms

Core Pharmaceutical Concepts

Drug Interactions[MeSH]
Main term for DDIs
Pharmacokinetics[MeSH]
ADME processes
Pharmacodynamics[MeSH]
Drug effects
Cytochrome P-450[MeSH]
Metabolism enzymes
Pharmaceutical Care[MeSH]
Clinical pharmacy practice
Medication Errors[MeSH]
Patient safety
Drug Monitoring[MeSH]
Therapeutic monitoring
Polypharmacy[MeSH]
Multiple medications

Clinical Conditions Pharmacists Encounter

Septic Shock[MeSH]
ICU pharmacy
Diabetes Mellitus[MeSH]
Ambulatory care
Hypertension[MeSH]
Community pharmacy
Heart Failure[MeSH]
Cardiology pharmacy
Renal Insufficiency[MeSH]
Dose adjustments
Liver Diseases[MeSH]
Hepatic impairment

🔍 Advanced Search Strategies

Study Design Filters

Cochrane Highly Sensitive RCT Filter
(randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals[mh] NOT humans[mh])

This is the gold standard for finding RCTs in PubMed, validated by Cochrane.

Pragmatic Observational Filter
(cohort[tiab] OR “cohort studies”[MeSH] OR case-control[tiab] OR “case-control studies”[MeSH] OR cross-sectional[tiab] OR “Cross-Sectional Studies”[MeSH] OR observational[tiab] OR retrospective[tiab] OR prospective[tiab])

Use for real-world evidence and outcomes research.

High-Quality Evidence Filter
(systematic review[ti] OR meta-analysis[pt] OR meta-analysis[ti] OR “systematic review”[ti] OR “meta analysis”[ti])

Perfect for evidence-based guidelines and protocols.

Date Limiting Strategies

Two Approaches to Date Limiting:

1UI Method: Use sidebar → Publication Dates → Custom range (e.g., 2019-2025)

2Query Method: Include in your search string:

AND (“2019/01/01″[Date – Publication] : “2025/12/31″[Date – Publication])

📝 Comprehensive Worked Examples

Example 1: Vasopressin in Septic Shock

Clinical Context:

Norepinephrine is first-line; vasopressin is second-line. The 2025 OVISS study suggests earlier vasopressin initiation.

1Broad Seed Search (MeSH + tiab):

(“Septic Shock”[MeSH] OR septic shock[tiab]) AND (“Vasopressins”[MeSH] OR vasopressin[tiab] OR argipressin[tiab]) NOT (animals[mh] NOT humans[mh])

2RCT-Focused Version:

(“Septic Shock”[MeSH] OR septic shock[tiab]) AND (“Vasopressins”[MeSH] OR vasopressin[tiab] OR argipressin[tiab]) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals[mh] NOT humans[mh])

Example 2: Drug-Drug Interactions with Warfarin

Clinical Scenario:

Community pharmacist needs evidence on clinically significant warfarin interactions.

(“Warfarin”[MeSH] OR warfarin[tiab] OR coumadin[tiab]) AND (“Drug Interactions”[MeSH] OR “drug interaction”[tiab] OR “drug interactions”[tiab]) AND (“Cytochrome P-450 CYP2C9″[MeSH] OR CYP2C9[tiab] OR “vitamin K”[tiab]) AND (“2018/01/01″[Date – Publication] : “2025/12/31″[Date – Publication]) NOT (animals[mh] NOT humans[mh])

Example 3: Medication Adherence in Diabetes

Clinical Question:

What interventions improve medication adherence in diabetic patients?

(“Diabetes Mellitus”[MeSH] OR diabetes[tiab]) AND (“Medication Adherence”[MeSH] OR “medication adherence”[tiab] OR “medication compliance”[tiab] OR “treatment adherence”[tiab]) AND (“Pharmaceutical Care”[MeSH] OR “pharmacist intervention”[tiab] OR “clinical pharmacist”[tiab]) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR trial[tiab]) AND (“2015/01/01″[Date – Publication] : “2025/12/31″[Date – Publication])

⚠️ Drug Interaction Research Strategies

Key MeSH Terms for Drug Interactions

Drug Interactions[MeSH]
Primary term
Drug Synergism[MeSH]
Additive effects
Drug Antagonism[MeSH]
Opposing effects
Cytochrome P-450 Enzyme System[MeSH]
Metabolism interactions
P-Glycoprotein[MeSH]
Transport interactions
Food-Drug Interactions[MeSH]
Nutrition interactions

Common CYP450 Interaction Searches

(“Cytochrome P-450 CYP3A”[MeSH] OR CYP3A4[tiab] OR CYP3A[tiab]) AND (“Drug Interactions”[MeSH] OR “drug interaction”[tiab]) AND (inhibitor[tiab] OR inducer[tiab] OR substrate[tiab])
(“P-Glycoprotein”[MeSH] OR “p-glycoprotein”[tiab] OR “pgp”[tiab] OR “MDR1″[tiab]) AND (“Drug Interactions”[MeSH] OR “drug transport”[tiab]) AND (substrate[tiab] OR inhibitor[tiab] OR inducer[tiab])

Specific Interaction Examples

Grapefruit-Drug Interactions:

(“Grapefruit”[MeSH] OR grapefruit[tiab]) AND (“Drug Interactions”[MeSH] OR “food-drug interaction”[tiab]) AND (“Cytochrome P-450 CYP3A”[MeSH] OR CYP3A4[tiab])

📋 Copy-Paste Templates

A. Therapy/RCT Template

(<POPULATION MeSH/tiab block>) AND (<INTERVENTION MeSH/tiab block>) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals[mh] NOT humans[mh]) AND (“YYYY/MM/DD”[Date – Publication] : “YYYY/MM/DD”[Date – Publication])

B. Observational Template

(<POPULATION MeSH/tiab block>) AND (<EXPOSURE/INTERVENTION MeSH/tiab block>) AND (cohort[tiab] OR “cohort studies”[MeSH] OR case-control[tiab] OR “case-control studies”[MeSH] OR cross-sectional[tiab] OR “Cross-Sectional Studies”[MeSH] OR observational[tiab] OR retrospective[tiab] OR prospective[tiab]) NOT (animals[mh] NOT humans[mh]) AND (“YYYY/MM/DD”[Date – Publication] : “YYYY/MM/DD”[Date – Publication])

C. Drug Interaction Template

(“<DRUG 1 NAME>”[MeSH] OR <drug1>[tiab] OR <synonym>[tiab]) AND (“<DRUG 2 NAME>”[MeSH] OR <drug2>[tiab] OR <synonym>[tiab]) AND (“Drug Interactions”[MeSH] OR “drug interaction”[tiab] OR “drug interactions”[tiab]) NOT (animals[mh] NOT humans[mh])

D. Pharmacokinetics Template

(“<DRUG NAME>”[MeSH] OR <drug>[tiab]) AND (“Pharmacokinetics”[MeSH] OR pharmacokinetic*[tiab] OR bioavailability[tiab] OR “area under curve”[tiab] OR AUC[tiab] OR clearance[tiab]) AND (“<POPULATION>”[MeSH] OR <population>[tiab]) NOT (animals[mh] NOT humans[mh])

🔧 Troubleshooting & Pro Tips

Common Issues & Solutions

🔍 Too Many Results?
• Add field tags ([ti] for key terms)
• Include MeSH subheadings
• Apply Article Type, Humans, and Date filters
• Use Narrow option in Clinical Queries
📊 Too Few Results?
• Remove quotes to re-enable ATM
• Use OR to include more synonyms
• Combine MeSH with [tiab]
• Check spelling and try broader terms
🎯 Phrase Issues?
• Try proximity: “term A term B”[tiab:~0]
• Drop quotes and use field tags
• Check Search Details for interpretation
📝 Reproducibility?
• Use Advanced → History to combine sets
• Save final strategy for future use
• Document your search approach
• Share search strings with colleagues

📚 Key Resources & Training

Essential Training Links

📋 PubMed Search Guide for Pharmacists | Master evidence-based practice with precision searching | 🔬 Last updated: August 2025

PACULit Newsletter March 14 –

PACULit Newsletter - March 14, 2025

High-Impact Studies Review — March 2025

Stay updated with breakthrough research in emergency medicine, critical care, and advanced therapeutics.

Featured Educational Video

In this episode, experts review key updates from the 2025 ACS guidelines, examine the emerging role of short‐acting beta-blockers and dexmedetomidine in septic shock, compare novel analgesic strategies using nebulized versus intravenous ketamine, and discuss the impact of tranexamic acid in pediatric traumatic brain injury.

1. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Acute Coronary Syndromes
JACC & Circulation | February 2025

The 2025 update to the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines for Acute Coronary Syndrome (ACS) introduces important changes based on the latest clinical evidence. The new recommendations focus on optimizing early risk stratification, refining antithrombotic therapy, and tailoring invasive management strategies to improve patient outcomes.

Key Updates and Findings

  • Dual Antiplatelet Therapy (DAPT): Used to be: Clopidogrel was often an equivalent option. Now: Ticagrelor or prasugrel is now the preferred P2Y12 inhibitor over clopidogrel in all patients undergoing PCI unless contraindicated.
  • ECG Timing and Risk Assessment: All patients with suspected ACS should have an ECG performed within 10 minutes of arrival to facilitate rapid classification and treatment initiation.
  • Radial vs. Femoral PCI Access: Radial artery access is strongly recommended over femoral access due to lower bleeding risks, fewer vascular complications, and reduced mortality.
  • Complete Revascularization Strategy: Routine PCI of non-culprit lesions in STEMI patients is not recommended during the initial procedure, except in cases of cardiogenic shock.
  • High-Intensity Statins and Lipid Management: High-intensity statins should be initiated in all ACS patients. If LDL remains ≥70 mg/dL, additional lipid-lowering agents (ezetimibe or PCSK9 inhibitors) should be considered.
  • Beta-Blocker Therapy: Used to be: For all, regardless of risk factors. Now: Early beta-blocker use is no longer required for all ACS patients. Therapy should be reserved for those with ongoing ischemia, hypertension, or left ventricular dysfunction.
  • Anticoagulation Strategy: Selection of unfractionated heparin (UFH), enoxaparin, or bivalirudin should be individualized based on renal function, prior anticoagulation, and bleeding risk.
  • Early Discharge for Low-Risk NSTEMI: Selected low-risk patients with negative troponins and normal ECG findings may be safely discharged within 24 hours with close outpatient follow-up.
  • Cardiogenic Shock Management: Emergency PCI should target the culprit vessel only. Non-culprit PCI at the time of intervention is discouraged unless clinically indicated.

Clinical Implications

These updates emphasize a more individualized approach to ACS management, balancing ischemic protection with bleeding risk. The move toward radial PCI access, a shift in beta-blocker recommendations, and an intensified focus on lipid-lowering strategies mark significant changes in clinical practice.

Clinical Pharmacist's Perspective

Pharmacists play a key role in ensuring appropriate DAPT selection, optimizing statin therapy adherence, and managing anticoagulation. The inclusion of PCSK9 inhibitors highlights the need for careful assessment of cost-effectiveness in high-risk patients. Close monitoring of potential drug interactions is also essential to ensure safe therapy implementation.

Full Article
2. Impact of Short-Acting Beta-Blockers in Septic Shock
Critical Care Medicine | 2025

This systematic review and meta-analysis of 12 randomized controlled trials (RCTs) involving 1,170 patients examined the effects of short-acting beta-blockers in septic shock. The findings suggest potential benefits in mortality reduction and heart rate control, but also raise concerns about prolonged vasopressor use.

Key Findings
  • Reduction in 28-Day Mortality: Short-acting beta-blockers were associated with a 24% relative reduction in 28-day mortality (RR 0.76, 95% CI 0.62–0.93).
  • New-Onset Tachyarrhythmia Prevention: Significant reduction in tachyarrhythmias (RR 0.37, 95% CI 0.18–0.78), suggesting improved heart rate control.
  • Impact on Hemodynamics: Beta-blockers stabilized heart rate but prolonged vasopressor requirements by an average of 1.04 days (95% CI 0.37–1.72).
  • No Clear Benefit on Long-Term Outcomes: No significant impact was observed on 90-day mortality, ICU length of stay, or mechanical ventilation duration.
Mechanism of Action

Beta-blockers such as esmolol and landiolol counteract excessive catecholamine stimulation, which can cause myocardial stress, endothelial injury, and metabolic dysfunction in septic shock. By reducing sympathetic overdrive, they may improve cardiac efficiency and tissue oxygenation while preventing secondary organ dysfunction.

Clinical Implications

The potential mortality benefit makes beta-blockers a promising adjunctive therapy in septic shock, particularly for patients with persistent tachycardia despite adequate fluid resuscitation and vasopressor therapy. However, the prolonged vasopressor requirements suggest that beta-blockers should be used selectively and with careful monitoring.

Clinical Pharmacist's Perspective

The use of beta-blockers in septic shock remains controversial and should be limited to patients who demonstrate clear benefit. Pharmacists should focus on:

  • Dosing and titration: Adjust doses carefully to prevent excessive bradycardia and hypotension.
  • Monitoring interactions: Watch for interactions with vasopressors and inotropes that could impact hemodynamics.
  • Assessing patient eligibility: Ensure beta-blockers are used in clinically stable individuals with controlled shock parameters.

As further studies emerge, pharmacists can help refine treatment protocols to integrate beta-blockers safely in select patients.

Full Article
3. Nebulized Ketamine vs IV Subdissociative Dose Ketamine for Acute Pain
Annals of Emergency Medicine | October 2024

In a randomized, double-blind trial of 150 adults, both nebulized (0.75 mg/kg) and IV (0.3 mg/kg) ketamine provided substantial pain relief at 30 minutes with comparable safety profiles.

Key Findings:
  • Both regimens significantly reduced pain scores.
  • No clinically significant differences in adverse effects.
  • Noninvasive nebulized administration may benefit patients without IV access.
Clinical Pharmacist's Perspective:

Ketamine offers an effective alternative for acute pain management; route selection can be tailored to clinical settings and patient needs.

Full Article
4. Dexmedetomidine in Refractory Septic Shock (ADRESS Trial)
Critical Care Medicine | 2025

This pilot trial evaluated dexmedetomidine (1 µg/kg/hr) for enhancing vasopressor sensitivity in refractory septic shock. The trial was halted early due to a lower phenylephrine response and higher early mortality in the dexmedetomidine group.

Key Findings:
  • Significantly lower MAP response to phenylephrine in the dexmedetomidine group.
  • Higher early mortality noted, raising safety concerns.
  • No significant improvements in vasopressor dose requirements.
Clinical Pharmacist's Perspective:

Given the safety signals, cautious use of dexmedetomidine is advised in septic shock until larger trials clarify its role.

Full Article
5. Tranexamic Acid in Pediatric Traumatic Brain Injury
Annals of Emergency Medicine | February 2025

A multicenter retrospective study of 368 pediatric severe TBI patients found that TXA administration was not associated with a reduction in inhospital mortality or poor neurologic outcomes.

Key Findings:
  • Inhospital mortality: 14% overall with no significant difference between TXA and non-TXA groups.
  • Poor neurologic outcomes were similar regardless of TXA use.
  • Results do not support routine TXA administration for severe pediatric TBI.
Clinical Pharmacist's Perspective:

TXA remains valuable in hemorrhagic trauma; however, its role in pediatric TBI is unproven and should be applied cautiously.

Full Article
🔎 Final Takeaways:
  • ACS Guidelines: Updated recommendations favor aggressive dual antiplatelet and radial access strategies.
  • Beta-Blockers: May lower short-term mortality in septic shock, but further research is needed to balance benefits with prolonged vasopressor use.
  • Ketamine: Both IV and nebulized routes offer effective, safe analgesia for acute pain.
  • Dexmedetomidine: Its use in refractory septic shock is not supported by current evidence due to safety concerns.
  • TXA in Pediatric TBI: No clear benefit was demonstrated, underscoring the need for prospective trials.
Join Our Elite Community of Healthcare Professionals

Receive curated insights in acute care, pharmacy, and specialized medicine directly in your inbox.

📚
Evidence-Based Updates

Access peer-reviewed research summaries and clinical practice updates

🎙️
Expert Podcasts

Listen to discussions with leading practitioners on cutting-edge approaches

🎥
Video Content

Watch educational content, procedure demos, and case study analyses

Subscribe to PACULit

PACU - Pharmacy & Acute Care University

Stay updated with the latest in critical care & emergency medicine.

© 2025 PACU. All rights reserved.

PACULit Newsletter March 3

PACULit Newsletter - March 3 2025

High-Impact Studies Review — March 2025

Stay updated with the latest breakthrough research in emergency medicine, critical care, and advanced therapeutics.

Featured Educational Video

This month's featured educational video provides an in-depth discussion on emerging treatments in emergency medicine and critical care. Our medical experts review the key research findings presented in this newsletter, with practical applications for your clinical practice.

1. Magnesium Sulfate vs. Lidocaine as an Adjunct for Renal Colic
Annals of Emergency Medicine | December 2024

This randomized, double-blind controlled trial compared the effectiveness of intravenous MgSO4 and lidocaine as adjuncts to diclofenac for managing acute renal colic in the emergency department setting.

Patients Achieving ≥50% Pain Reduction at 30 Minutes
81.7%
MgSO4
72.9%
Lidocaine
71.8%
Control
Statistically significant differences: MgSO4 vs. Lidocaine (p=0.013) and MgSO4 vs. Control (p=0.004)
Key Findings:
  • MgSO4 showed statistically superior pain relief compared to lidocaine and placebo
  • The magnitude of differences was below the accepted threshold for clinical importance
  • MgSO4 group required less rescue analgesia
  • More adverse events in the MgSO4 group, primarily facial flushing (48.2%)
Clinical Implications:
  • Use MgSO4 cautiously, balancing marginal benefits with adverse event risks
  • Lidocaine showed no major benefit over diclofenac alone
Clinical Pharmacist's Perspective

The modest analgesic benefit of IV magnesium must be weighed against the high incidence of facial flushing (48.2%). When administering IV MgSO4, ensure patients are warned about this common side effect to prevent unnecessary anxiety. From a cost perspective, MgSO4 is an inexpensive adjunct that may reduce the need for opioid rescue medication. Consider it in patients with contraindications to opioids or those with prior inadequate response to NSAIDs alone. The 1g dose used in this study is well below the threshold for serious toxicity, making it relatively safe even in patients with mild renal impairment.

Full Article
2. Intranasal Ketamine as an Adjunct to Fentanyl for Prehospital Trauma Pain
Annals of Emergency Medicine | October 2024 (Epub January 12, 2024)

This randomized, placebo-controlled trial evaluated whether adding intranasal ketamine to fentanyl improves early pain control after traumatic injury in the out-of-hospital setting.

Patients Achieving ≥2-Point Pain Reduction at 30 Minutes
44.7%
Ketamine
36.0%
Placebo
Difference not statistically significant (8.7%, 95% CI [5.1% to 22.5%], P=0.22)
Key Findings:
  • No statistically significant difference in pain reduction between ketamine (44.7%) and placebo (36.0%)
  • The observed difference of 8.7% suggests a trend that might warrant further investigation
  • No differences in pain scores at any time point through 3 hours
  • No difference in need for additional pain medications
  • Side effects were similar between groups with no concerning safety signals
Clinical Implications:
  • A single 50 mg intranasal dose of ketamine appears safe but current evidence doesn't support a significant analgesic benefit
  • Higher doses might be worth exploring in future studies
Clinical Pharmacist's Perspective

The bioavailability of intranasal ketamine is approximately 40%, meaning the 50mg dose used in this study translates to roughly 20mg of systemic exposure. This is likely at the lower end of effective analgesic dosing for adults. While the observed 8.7% improvement didn't reach statistical significance, this trend suggests that higher doses might be more effective. For EMS protocols, intranasal administration remains attractive for its ease of use and avoidance of vascular access, but based on this study, higher intranasal doses (75-100mg) may be worth investigating. Remember that absorption of intranasal medications can be compromised by nasal congestion, bleeding, or prior intranasal medication administration, which may have affected the results here.

Full Article
3. Transfusion Practices in Traumatic Brain Injury (TBI): A Systematic Review & Meta-Analysis
Critical Care Medicine | February 2025

This comprehensive review examined whether liberal blood transfusion strategies improve neurologic outcomes in TBI patients compared to restrictive strategies across five randomized controlled trials involving 1,533 patients.

Neurologic Outcomes (Favorable Glasgow Outcome Scale)
1.16
Liberal
1.00
Restrictive
Risk Ratio: 1.16 (95% CI 1.00-1.34)
Acute Respiratory Distress Syndrome (ARDS) Risk
1.78
Liberal
1.00
Restrictive
Risk Ratio: 1.78 (95% CI 1.06-2.98)
Key Findings:
  • Trend toward better neurologic outcomes with liberal transfusion that approaches statistical significance (RR, 1.16; 95% CI, 1.00-1.34)
  • No significant differences in mortality rates between groups at any time point
  • Liberal strategy was associated with significantly higher prevalence of ARDS (RR, 1.78; 95% CI, 1.06-2.98)
  • Liberal strategy group received significantly more blood units per patient
Clinical Implications:
  • Current guidelines recommending restrictive transfusion protocols (Hb < 7 g/dL) should be reconsidered for TBI patients
  • The 9 g/dL threshold may represent an optimal balance between brain oxygenation and transfusion risks
  • Despite increased ARDS risk, the potential neurologic benefits should be considered when making transfusion decisions
  • Future research should explore the ideal hemoglobin threshold specifically for TBI patients
Clinical Pharmacist's Perspective

While pharmacists don't directly administer blood products, understanding transfusion thresholds is essential for comprehensive patient care in critical care settings. This meta-analysis suggests a potential paradigm shift for TBI patients that differs from general critical care guidelines. As part of the multidisciplinary team, pharmacists should be aware that TBI patients may benefit from higher hemoglobin targets due to the brain's high oxygen demands and vulnerability to hypoxic injury. When managing patients receiving liberal transfusion strategies, be vigilant for signs of ARDS and consider how medication therapies might interact with fluid status and oxygen delivery. Pharmacists can play a role in ensuring appropriate venous thromboembolism prophylaxis is prescribed alongside transfusion strategies, as both hypercoagulable and bleeding risk considerations must be balanced in TBI care.

Full Article
🔎 Final Takeaways:
  • Magnesium Sulfate for Renal Colic: Provides statistically significant but clinically modest improvement in pain when added to diclofenac. Consider in patients who need enhanced analgesia, but be mindful of facial flushing as a common side effect.
  • Intranasal Ketamine for Trauma Pain: The addition of 50 mg intranasal ketamine to fentanyl showed a trend toward improved pain control (8.7% difference) that didn't reach statistical significance. Further research with larger sample sizes or higher doses may be warranted.
  • Liberal Transfusion in TBI: Evidence suggests that maintaining hemoglobin levels ≥9 g/dL may improve neurologic outcomes in TBI patients, but also increases ARDS risk. This challenges the standard restrictive approach and warrants further investigation.
Join Our Elite Community of Healthcare Professionals

Receive curated insights in acute care, pharmacy, and specialized medicine directly in your inbox.

📚
Evidence-Based Updates

Access peer-reviewed research summaries and clinical practice updates

🎙️
Expert Podcasts

Listen to discussions with leading practitioners on cutting-edge approaches

🎥
Video Content

Watch educational content, procedure demos, and case study analyses

Subscribe to PACULit

PACU - Pharmacy & Acute Care University

Stay updated with the latest in critical care & emergency medicine.

© 2025 PACU. All rights reserved.

ACURASYS

You are unauthorized to view this page.

BICAR-ICU

You are unauthorized to view this page.